{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:56:27Z","timestamp":1793094987598,"version":"4.5.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04311-4","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:21:43Z","timestamp":1773746503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy"],"prefix":"10.1007","volume":"75","author":[{"given":"K\u00fcbra","family":"Canaslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Moeini Nia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Baez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Abolhassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Ridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroun","family":"Bou Zerdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain","family":"Rangoonwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnaz","family":"Jahanbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Emami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesim","family":"G\u00f6kmen-Polar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil S.","family":"Badve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swasthik","family":"Upadhya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Galateau Salle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badi","family":"El Olsta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong M.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Ardeshir-larijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"7","key":"4311_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101621","volume":"5","author":"H Yamaguchi","year":"2024","unstructured":"Yamaguchi H, Hsu JM, Sun L, Wang SC, Hung MC (2024) Advances and prospects of biomarkers for immune checkpoint inhibitors. Cell Rep Med 5(7):101621. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101621","journal-title":"Cell Rep Med"},{"issue":"5","key":"4311_CR2","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1093\/oncolo\/oyae013","volume":"29","author":"DC Guven","year":"2024","unstructured":"Guven DC, Kavgaci G, Erul E, Syed MP, Magge T, Saeed A et al (2024) The efficacy of immune checkpoint inhibitors in microsatellite stable colorectal cancer: a systematic review. Oncologist 29(5):e580\u2013e600. https:\/\/doi.org\/10.1093\/oncolo\/oyae013","journal-title":"Oncologist"},{"issue":"11","key":"4311_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103967","volume":"9","author":"V Formica","year":"2024","unstructured":"Formica V, Morelli C, Fornaro L, Riondino S, Rofei M, Fontana E et al (2024) PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase IIIrandomized trials. ESMO Open 9(11):103967. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103967","journal-title":"ESMO Open"},{"issue":"2","key":"4311_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY et al (2019) Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51(2):202\u2013206. https:\/\/doi.org\/10.1038\/s41588-018-0312-8","journal-title":"Nat Genet"},{"issue":"3","key":"4311_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031554","volume":"25","author":"L Elm","year":"2024","unstructured":"Elm L, Levidou G (2024) The molecular landscape of thymic epithelial tumors: a comprehensive review. Int J Mol Sci 25(3):1554. https:\/\/doi.org\/10.3390\/ijms25031554","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4311_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092060","volume":"14","author":"M Ballman","year":"2022","unstructured":"Ballman M, Zhao C, McAdams MJ, Rajan A (2022) Immunotherapy for management of thymic epithelial tumors: a double-edged sword. Cancers (Basel) 14(9):2060. https:\/\/doi.org\/10.3390\/cancers14092060","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4311_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-019-0177-8","volume":"7","author":"I Rouquette","year":"2019","unstructured":"Rouquette I, Taranchon-Clermont E, Gilhodes J, Bluthgen MV, Perallon R, Chalabreysse L et al (2019) Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1. Biomark Res 7(1):28. https:\/\/doi.org\/10.1186\/s40364-019-0177-8","journal-title":"Biomark Res"},{"issue":"6","key":"4311_CR8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/modpathol.2017.6","volume":"30","author":"A Weissferdt","year":"2017","unstructured":"Weissferdt A, Fujimoto J, Kalhor N, Rodriguez J, Bassett R, Wistuba II et al (2017) Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol 30(6):826\u2013833. https:\/\/doi.org\/10.1038\/modpathol.2017.6","journal-title":"Mod Pathol"},{"issue":"1-3","key":"4311_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12026-012-8301-y","volume":"54","author":"K Alexandropoulos","year":"2012","unstructured":"Alexandropoulos K, Danzl NM (2012) Thymic epithelial cells: antigen presenting cells that regulate T cell repertoire and tolerance development. Immunol Res 54(1\u20133):177\u2013190. https:\/\/doi.org\/10.1007\/s12026-012-8301-y","journal-title":"Immunol Res"},{"issue":"4","key":"4311_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1365-2567.2011.03547.x","volume":"135","author":"AE Moran","year":"2012","unstructured":"Moran AE, Hogquist KA (2012) T-cell receptor affinity in thymic development. Immunology 135(4):261\u2013267. https:\/\/doi.org\/10.1111\/j.1365-2567.2011.03547.x","journal-title":"Immunology"},{"issue":"7","key":"4311_CR11","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00109-022-02215-1","volume":"100","author":"N H\u00f6velmeyer","year":"2022","unstructured":"H\u00f6velmeyer N, Schmidt-Supprian M, Ohnmacht C (2022) NF-\u03baB in control of regulatory T cell development, identity, and function. J Mol Med (Berl) 100(7):985\u2013995. https:\/\/doi.org\/10.1007\/s00109-022-02215-1","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"4311_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/imr.12404","volume":"271","author":"I Ohigashi","year":"2016","unstructured":"Ohigashi I, Kozai M, Takahama Y (2016) Development and developmental potential of cortical thymic epithelial cells. Immunol Rev 271(1):10\u201322. https:\/\/doi.org\/10.1111\/imr.12404","journal-title":"Immunol Rev"},{"issue":"1","key":"4311_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/35095500","volume":"1","author":"G Anderson","year":"2001","unstructured":"Anderson G, Jenkinson EJ (2001) Lymphostromal interactions in thymic development and function. Nat Rev Immunol 1(1):31\u201340. https:\/\/doi.org\/10.1038\/35095500","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"4311_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-022-00211-z","volume":"42","author":"R Benlaribi","year":"2022","unstructured":"Benlaribi R, Gou Q, Takaba H (2022) Thymic self-antigen expression for immune tolerance and surveillance. Inflamm Regen 42(1):28. https:\/\/doi.org\/10.1186\/s41232-022-00211-z","journal-title":"Inflamm Regen"},{"issue":"4","key":"4311_CR15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.cell.2015.10.013","volume":"163","author":"H Takaba","year":"2015","unstructured":"Takaba H, Morishita Y, Tomofuji Y, Danks L, Nitta T, Komatsu N et al (2015) Fezf2 orchestrates a thymic program of self-antigen expression for immune tolerance. Cell 163(4):975\u2013987. https:\/\/doi.org\/10.1016\/j.cell.2015.10.013","journal-title":"Cell"},{"issue":"1","key":"4311_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1079-9","volume":"17","author":"M Danan-Gotthold","year":"2016","unstructured":"Danan-Gotthold M, Guyon C, Giraud M, Levanon EY, Abramson J (2016) Extensive RNA editing and splicing increase immune self-representation diversity in medullary thymic epithelial cells. Genome Biol 17(1):219. https:\/\/doi.org\/10.1186\/s13059-016-1079-9","journal-title":"Genome Biol"},{"issue":"12","key":"4311_CR17","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1101\/gr.171645.113","volume":"24","author":"SN Sansom","year":"2014","unstructured":"Sansom SN, Shikama-Dorn N, Zhanybekova S, Nusspaumer G, Macaulay IC, Deadman ME et al (2014) Population and single-cell genomics reveal the Aire dependency, relief from Polycomb silencing, and distribution of self-antigen expression in thymic epithelia. Genome Res 24(12):1918\u20131931. https:\/\/doi.org\/10.1101\/gr.171645.113","journal-title":"Genome Res"},{"key":"4311_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00187","volume":"4","author":"R Romano","year":"2013","unstructured":"Romano R, Palamaro L, Fusco A, Giardino G, Gallo V, Del Vecchio L et al (2013) FOXN1: a master regulator gene of thymic epithelial development program. Front Immunol 4:187. https:\/\/doi.org\/10.3389\/fimmu.2013.00187","journal-title":"Front Immunol"},{"issue":"1","key":"4311_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33170-7","volume":"13","author":"Z Xin","year":"2022","unstructured":"Xin Z, Lin M, Hao Z, Chen D, Chen Y, Chen X et al (2022) The immune landscape of human thymic epithelial tumors. Nat Commun 13(1):5463. https:\/\/doi.org\/10.1038\/s41467-022-33170-7","journal-title":"Nat Commun"},{"issue":"7","key":"4311_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0661-2","volume":"20","author":"EA Lippner","year":"2019","unstructured":"Lippner EA, Lewis DB, Robinson WH, Katsumoto TR (2019) Paraneoplastic and therapy-related immune complications in thymic malignancies. Curr Treat Options Oncol 20(7):62. https:\/\/doi.org\/10.1007\/s11864-019-0661-2","journal-title":"Curr Treat Options Oncol"},{"issue":"10 Suppl 4","key":"4311_CR21","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.1097\/JTO.0b013e3181f1f63f","volume":"5","author":"A Marx","year":"2010","unstructured":"Marx A, Hohenberger P, Hoffmann H, Pfannschmidt J, Schnabel P, Hofmann HS et al (2010) The autoimmune regulator AIRE in thymoma biology: autoimmunity and beyond. J Thorac Oncol 5(10 Suppl 4):S266\u2013S272. https:\/\/doi.org\/10.1097\/JTO.0b013e3181f1f63f","journal-title":"J Thorac Oncol"},{"issue":"4","key":"4311_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/hmg\/11.4.397","volume":"11","author":"C Ramsey","year":"2002","unstructured":"Ramsey C, Winqvist O, Puhakka L, Halonen M, Moro A, K\u00e4mpe O et al (2002) Aire deficient mice develop multiple features of APECED phenotype and show altered immune response. Hum Mol Genet 11(4):397\u2013409. https:\/\/doi.org\/10.1093\/hmg\/11.4.397","journal-title":"Hum Mol Genet"},{"issue":"1","key":"4311_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00395-024-01070-0","volume":"120","author":"F Buehning","year":"2025","unstructured":"Buehning F, Lerchner T, Vogel J, Hendgen-Cotta UB, Totzeck M, Rassaf T et al (2025) Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy. Basic Res Cardiol 120(1):171\u2013185. https:\/\/doi.org\/10.1007\/s00395-024-01070-0","journal-title":"Basic Res Cardiol"},{"issue":"6","key":"4311_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.sult.2024.07.006","volume":"45","author":"V Sorin","year":"2024","unstructured":"Sorin V, Kirshenboim Z, Klug M, Ahuja J, Marom EM (2024) The ninth edition TNM staging classification for thymic epithelial tumors. Semin Ultrasound CT MR 45(6):420\u2013429. https:\/\/doi.org\/10.1053\/j.sult.2024.07.006","journal-title":"Semin Ultrasound CT MR"},{"key":"4311_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorc.2025.100027","volume":"4","author":"C Basse","year":"2025","unstructured":"Basse C, Gagnepain E, Chalabreysse L, Bonte PE, Meurgey A, Maury JM et al (2025) Stage shift from Masaoka-Koga to ninth TNM system in thymic epithelial tumors. ESMO Rare Cancers 4:100027","journal-title":"ESMO Rare Cancers"},{"key":"4311_CR26","unstructured":"WHO Classification of Tumours Editorial Board. Thoracic Tumours. In: WHO classification of tumours series.5th ed. 5. Lyon, France: International Agency for Research on Cancer; 2021."},{"issue":"1","key":"4311_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/his.15097","volume":"84","author":"J von der Th\u00fcsen","year":"2024","unstructured":"von der Th\u00fcsen J (2024) Thymic epithelial tumours: histopathological classification and differential diagnosis. Histopathology 84(1):196\u2013215. https:\/\/doi.org\/10.1111\/his.15097","journal-title":"Histopathology"},{"issue":"5","key":"4311_CR28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jtho.2022.01.021","volume":"17","author":"AC Roden","year":"2022","unstructured":"Roden AC, Ahmad U, Cardillo G, Girard N, Jain D, Marom EM et al (2022) Thymic carcinomas-a concise multidisciplinary update on recent developments from the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group. J Thorac Oncol 17(5):637\u2013650. https:\/\/doi.org\/10.1016\/j.jtho.2022.01.021","journal-title":"J Thorac Oncol"},{"issue":"3","key":"4311_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jtho.2017.11.118","volume":"13","author":"SK Padda","year":"2018","unstructured":"Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB et al (2018) Paraneoplastic syndromes and thymic malignancies: an examination of the International Thymic Malignancy Interest Group retrospective database. J Thorac Oncol 13(3):436\u2013446. https:\/\/doi.org\/10.1016\/j.jtho.2017.11.118","journal-title":"J Thorac Oncol"},{"issue":"2","key":"4311_CR30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/JTO.0000000000000393","volume":"10","author":"CA Weis","year":"2015","unstructured":"Weis CA, Yao X, Deng Y, Detterbeck FC, Marino M, Nicholson AG et al (2015) The impact of thymoma histotype on prognosis in a worldwide database. J Thorac Oncol 10(2):367\u2013372. https:\/\/doi.org\/10.1097\/JTO.0000000000000393","journal-title":"J Thorac Oncol"},{"issue":"12","key":"4311_CR31","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/modpathol.2010.172","volume":"23","author":"RK Jain","year":"2010","unstructured":"Jain RK, Mehta RJ, Henley JD, Kesler KA, Loehrer PJ, Badve S (2010) WHO types A and AB thymomas: not always benign. Mod Pathol 23(12):1641\u20131649. https:\/\/doi.org\/10.1038\/modpathol.2010.172","journal-title":"Mod Pathol"},{"issue":"2","key":"4311_CR32","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","volume":"33","author":"M Radovich","year":"2018","unstructured":"Radovich M, Pickering CR, Felau I et al (2018) The integrated genomic landscape of thymic epithelial tumors. Cancer Cell 33(2):244-258.e10. https:\/\/doi.org\/10.1016\/j.ccell.2018.01.003","journal-title":"Cancer Cell"},{"issue":"4","key":"4311_CR33","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/bjc.2015.425","volume":"114","author":"M Radovich","year":"2016","unstructured":"Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H et al (2016) A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas. Br J Cancer 114(4):477\u2013484. https:\/\/doi.org\/10.1038\/bjc.2015.425","journal-title":"Br J Cancer"},{"issue":"14","key":"4311_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143388","volume":"14","author":"A Szpechcinski","year":"2022","unstructured":"Szpechcinski A, Szolkowska M, Winiarski S, Lechowicz U, Wisniewski P, Knetki-Wroblewska M (2022) Targeted next-generation sequencing of thymic epithelial tumours revealed pathogenic variants in KIT, ERBB2, KRAS, and TP53 in 30% of thymic carcinomas. Cancers (Basel) 14(14):3388. https:\/\/doi.org\/10.3390\/cancers14143388","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4311_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cllc.2020.11.010","volume":"22","author":"T Sakane","year":"2021","unstructured":"Sakane T, Sakamoto Y, Masaki A, Murase T, Okuda K, Nakanishi R et al (2021) Mutation profile of thymic carcinoma and thymic neuroendocrine tumor by targeted next-generation sequencing. Clin Lung Cancer 22(2):92-99.e4. https:\/\/doi.org\/10.1016\/j.cllc.2020.11.010","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"4311_CR36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2478\/raon-2023-0013","volume":"57","author":"J Kostic Peric","year":"2023","unstructured":"Kostic Peric J, Cirkovic A, Srzentic Drazilov S, Samardzic N, Skodric Trifunovic V, Jovanovic D et al (2023) Molecular profiling of rare thymoma using next-generation sequencing: meta-analysis. Radiol Oncol 57(1):12\u201319. https:\/\/doi.org\/10.2478\/raon-2023-0013","journal-title":"Radiol Oncol"},{"key":"4311_CR37","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00465","volume":"7","author":"F Ardeshir-Larijani","year":"2023","unstructured":"Ardeshir-Larijani F, Schneider BP, Althouse SK, Radovich M, Masood A, Perna F et al (2023) Clinicogenomic landscape of metastatic thymic epithelial tumors. JCO Precis Oncol 7:e2200465. https:\/\/doi.org\/10.1200\/PO.22.00465","journal-title":"JCO Precis Oncol"},{"key":"4311_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1264325","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang P, Cong A, Feng Y, Chi H, Xia Z et al (2023) Unraveling molecular networks in thymic epithelial tumors: deciphering the unique signatures. Front Immunol 14:1264325. https:\/\/doi.org\/10.3389\/fimmu.2023.1264325","journal-title":"Front Immunol"},{"issue":"8","key":"4311_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042669","volume":"7","author":"S Badve","year":"2012","unstructured":"Badve S, Goswami C, G\u00f6kmen-Polar Y, Nelson RP Jr, Henley J, Miller N et al (2012) Molecular analysis of thymoma. PLoS ONE 7(8):e42669. https:\/\/doi.org\/10.1371\/journal.pone.0042669","journal-title":"PLoS ONE"},{"issue":"7","key":"4311_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066047","volume":"8","author":"Y G\u00f6kmen-Polar","year":"2013","unstructured":"G\u00f6kmen-Polar Y, Cook RW, Goswami CP, Wilkinson J, Maetzold D, Stone JF et al (2013) A gene signature to determine metastatic behavior in thymomas. PLoS ONE 8(7):e66047. https:\/\/doi.org\/10.1371\/journal.pone.0066047","journal-title":"PLoS ONE"},{"issue":"24","key":"4311_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246082","volume":"14","author":"AC Agrafiotis","year":"2022","unstructured":"Agrafiotis AC, Siozopoulou V, Hendriks JMH, Pauwels P, Koljenovic S, Van Schil PE (2022) Tumor microenvironment in thymic epithelial tumors: a narrative review. Cancers (Basel) 14(24):6082. https:\/\/doi.org\/10.3390\/cancers14246082","journal-title":"Cancers (Basel)"},{"issue":"9 Suppl 2","key":"4311_CR42","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.1097\/JTO.0000000000000299","volume":"9","author":"B Weksler","year":"2014","unstructured":"Weksler B, Lu B (2014) Alterations of the immune system in thymic malignancies. J Thorac Oncol 9(9 Suppl 2):S137\u2013S142. https:\/\/doi.org\/10.1097\/JTO.0000000000000299","journal-title":"J Thorac Oncol"},{"key":"4311_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1288045","volume":"15","author":"M Perrino","year":"2024","unstructured":"Perrino M, Voulaz E, Balin S, Cazzato G, Fontana E, Franzese S et al (2024) Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs. Front Immunol 15:1288045. https:\/\/doi.org\/10.3389\/fimmu.2024.1288045","journal-title":"Front Immunol"},{"issue":"1","key":"4311_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-04002-7","volume":"5","author":"OB Giorgetti","year":"2022","unstructured":"Giorgetti OB, Nusser A, Boehm T (2022) Human thymoma-associated mutation of the GTF2I transcription factor impairs thymic epithelial progenitor differentiation in mice. Commun Biol 5(1):1037. https:\/\/doi.org\/10.1038\/s42003-022-04002-7","journal-title":"Commun Biol"},{"key":"4311_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2022.06.059","volume":"174","author":"W Wang","year":"2022","unstructured":"Wang W, Lin G, Hao Y, Guan Y, Zhang Y, Xu C et al (2022) Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: a multicentre retrospective study. Eur J Cancer 174:21\u201330. https:\/\/doi.org\/10.1016\/j.ejca.2022.06.059","journal-title":"Eur J Cancer"},{"issue":"2","key":"4311_CR46","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s12094-024-03618-x","volume":"27","author":"H Si","year":"2025","unstructured":"Si H, Fu X, Hao Y, Wang Y, Lin G, Wang D et al (2025) The influence of PD-L1 expression levels on the efficacy of combination therapy in thymic epithelial tumors. Clin Transl Oncol 27(2):542\u2013548. https:\/\/doi.org\/10.1007\/s12094-024-03618-x","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"4311_CR47","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S1470-2045(22)00542-3","volume":"23","author":"F Conforti","year":"2022","unstructured":"Conforti F, Zucali PA, Pala L, Catania C, Bagnardi V, Sala I et al (2022) Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. Lancet Oncol 23(10):1287\u20131296. https:\/\/doi.org\/10.1016\/S1470-2045(22)00542-3","journal-title":"Lancet Oncol"},{"issue":"3","key":"4311_CR48","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","volume":"19","author":"G Giaccone","year":"2018","unstructured":"Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ et al (2018) Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 19(3):347\u2013355. https:\/\/doi.org\/10.1016\/S1470-2045(18)30062-7","journal-title":"Lancet Oncol"},{"issue":"1","key":"4311_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01772-4","volume":"22","author":"YQ Ao","year":"2023","unstructured":"Ao YQ, Gao J, Wang S, Jiang JH, Deng J, Wang HK et al (2023) Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives. Mol Cancer 22(1):70. https:\/\/doi.org\/10.1186\/s12943-023-01772-4","journal-title":"Mol Cancer"},{"issue":"7","key":"4311_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071369","volume":"16","author":"A Rajan","year":"2024","unstructured":"Rajan A, Sivapiromrat AK, McAdams MJ (2024) Immunotherapy for thymomas and thymic carcinomas: current status and future directions. Cancers (Basel) 16(7):1369. https:\/\/doi.org\/10.3390\/cancers16071369","journal-title":"Cancers (Basel)"},{"issue":"23","key":"4311_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21239056","volume":"21","author":"V Tateo","year":"2020","unstructured":"Tateo V, Manuzzi L, De Giglio A, Parisi C, Lamberti G, Campana D et al (2020) Immunobiology of thymic epithelial tumors: implications for immunotherapy with immune checkpoint inhibitors. Int J Mol Sci 21(23):9056. https:\/\/doi.org\/10.3390\/ijms21239056","journal-title":"Int J Mol Sci"},{"issue":"12","key":"4311_CR52","doi-asserted-by":"publisher","first-page":"7571","DOI":"10.21037\/jtd-2019-thym-10","volume":"12","author":"TG Blum","year":"2020","unstructured":"Blum TG, Misch D, Kollmeier J, Thiel S, Bauer TT (2020) Autoimmune disorders and paraneoplastic syndromes in thymoma. J Thorac Dis 12(12):7571\u20137590. https:\/\/doi.org\/10.21037\/jtd-2019-thym-10","journal-title":"J Thorac Dis"},{"key":"4311_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.808019","volume":"12","author":"D Alqaidy","year":"2022","unstructured":"Alqaidy D, Moran CA (2022) Thymic carcinoma: a review. Front Oncol 12:808019. https:\/\/doi.org\/10.3389\/fonc.2022.808019","journal-title":"Front Oncol"},{"key":"4311_CR54","unstructured":"Created in BioRender. Mieini, F & Baez, M. (2025)\u00a0https:\/\/BioRender.com\/ov24vrv (Accessed November 29, 2025)"},{"issue":"1","key":"4311_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00281-020-00835-8","volume":"43","author":"R Bacchetta","year":"2021","unstructured":"Bacchetta R, Weinberg K (2021) Thymic origins of autoimmunity-lessons from inborn errors of immunity. Semin Immunopathol 43(1):65\u201383. https:\/\/doi.org\/10.1007\/s00281-020-00835-8","journal-title":"Semin Immunopathol"},{"key":"4311_CR56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.lungcan.2019.06.015","volume":"135","author":"T Konstantina","year":"2019","unstructured":"Konstantina T, Konstantinos R, Anastasios K, Anastasia M, Eleni L, Ioannis S et al (2019) Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review. Lung Cancer 135:29\u201332. https:\/\/doi.org\/10.1016\/j.lungcan.2019.06.015","journal-title":"Lung Cancer"},{"key":"4311_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108554","volume":"204","author":"V Pavese","year":"2025","unstructured":"Pavese V, Carf\u00ec FM, Capelletto E, Tabb\u00f2 F, Leo F, Passiglia F et al (2025) Therapeutic management of patients with advanced thymic malignancies: a review for clinicians. Lung Cancer 204:108554. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108554","journal-title":"Lung Cancer"},{"key":"4311_CR58","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejca.2022.12.005","volume":"180","author":"J Remon","year":"2023","unstructured":"Remon J, Villacampa G, Facchinetti F, Di Maio M, Marcuse F, Tiseo M et al (2023) Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: a meta-analysis. Eur J Cancer 180:117\u2013124. https:\/\/doi.org\/10.1016\/j.ejca.2022.12.005","journal-title":"Eur J Cancer"},{"key":"4311_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/mog2.31","volume":"2","author":"J Yin","year":"2023","unstructured":"Yin J, Yao Z, Pan J, Gan L, Xue J (2023) Immune checkpoint inhibitor-related myocarditis in thymic epithelial tumors: recent progress and perspectives. MedComm\u2014Oncol 2:e31. https:\/\/doi.org\/10.1002\/mog2.31","journal-title":"MedComm\u2014Oncol"},{"key":"4311_CR60","doi-asserted-by":"publisher","first-page":"8016","DOI":"10.1200\/JCO.2025.43.16_suppl.8016","volume":"43","author":"N Girard","year":"2025","unstructured":"Girard N, Besse B, Duruisseaux M, Greillier L, Berghmans T, Pardo N et al (2025) Efficacy and safety of nivolumab plus ipilimumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. J Clin Oncol 43:8016\u20138016. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8016","journal-title":"J Clin Oncol"},{"issue":"18","key":"4311_CR61","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1002\/cam4.4711","volume":"11","author":"WL Ma","year":"2022","unstructured":"Ma WL, Lin CC, Hsu FM, Lee JM, Chen JS, Huang YL et al (2022) Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens. Cancer Med 11(18):3445\u20133456. https:\/\/doi.org\/10.1002\/cam4.4711","journal-title":"Cancer Med"},{"key":"4311_CR62","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2018.10.018","volume":"126","author":"T Berghmans","year":"2018","unstructured":"Berghmans T, Durieux V, Holbrechts S, Jungels C, Lafitte JJ, Meert AP et al (2018) Systemic treatments for thymoma and thymic carcinoma: a systematic review. Lung Cancer 126:25\u201331. https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.018","journal-title":"Lung Cancer"},{"issue":"3","key":"4311_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101576","volume":"8","author":"N Girard","year":"2023","unstructured":"Girard N, Ponce Aix S, Cedres S, Berghmans T, Burgers S, Toffart AC et al (2023) Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. ESMO Open 8(3):101576. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101576","journal-title":"ESMO Open"},{"key":"4311_CR64","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","volume":"113","author":"Y Katsuya","year":"2019","unstructured":"Katsuya Y, Horinouchi H, Seto T, Umemura S, Hosomi Y, Satouchi M et al (2019) Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer 113:78\u201386. https:\/\/doi.org\/10.1016\/j.ejca.2019.03.012","journal-title":"Eur J Cancer"},{"issue":"3","key":"4311_CR65","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1470-2045(25)00001-4","volume":"26","author":"T Shukuya","year":"2025","unstructured":"Shukuya T, Asao T, Goto Y, Mimori T, Takayama K, Kaira K et al (2025) Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial. Lancet Oncol 26(3):331\u2013342. https:\/\/doi.org\/10.1016\/S1470-2045(25)00001-4","journal-title":"Lancet Oncol"},{"key":"4311_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.968","volume":"34","author":"W Fang","year":"2023","unstructured":"Fang W, Wang C, Li J, Chen M, Ji Y, Fan H et al (2023) 2186P KN046 in patients with thymic carcinoma: a prospective, single-arm, multi-centre, phase II study. Ann Oncol 34:S1132","journal-title":"Ann Oncol"},{"issue":"1","key":"4311_CR67","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/CCO.0000000000001101","volume":"37","author":"B Kiesewetter","year":"2025","unstructured":"Kiesewetter B, Melhorn P, Fuereder T (2025) Thymic malignancies: role of immunotherapy and novel approaches. Curr Opin Oncol 37(1):84\u201394. https:\/\/doi.org\/10.1097\/CCO.0000000000001101","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"4311_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0974-6","volume":"18","author":"M Yi","year":"2019","unstructured":"Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A (2019) Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer 18(1):60. https:\/\/doi.org\/10.1186\/s12943-019-0974-6","journal-title":"Mol Cancer"},{"issue":"2","key":"4311_CR69","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","volume":"16","author":"A Thomas","year":"2015","unstructured":"Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ et al (2015) Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 16(2):177\u2013186. https:\/\/doi.org\/10.1016\/S1470-2045(14)71181-7","journal-title":"Lancet Oncol"},{"issue":"6","key":"4311_CR70","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","volume":"21","author":"J Sato","year":"2020","unstructured":"Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H et al (2020) Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol 21(6):843\u2013850. https:\/\/doi.org\/10.1016\/S1470-2045(20)30162-5","journal-title":"Lancet Oncol"},{"issue":"2","key":"4311_CR71","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2024.14516","volume":"28","author":"K Chiba","year":"2024","unstructured":"Chiba K, Murase T, Yokota K, Tatematsu T, Oda R, Nakamura R et al (2024) Expression of vascular endothelial growth factor receptor in thymic epithelial tumors. Oncol Lett 28(2):383. https:\/\/doi.org\/10.3892\/ol.2024.14516","journal-title":"Oncol Lett"},{"issue":"12","key":"4311_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100738","volume":"5","author":"AS Tsao","year":"2024","unstructured":"Tsao AS, Hsieh MH, Koczywas M, Tu J, Riess J, Tanvetyanon T et al (2024) S1701, a randomized phase 2 trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma. JTO Clin Res Rep 5(12):100738. https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100738","journal-title":"JTO Clin Res Rep"},{"issue":"9","key":"4311_CR73","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.annonc.2024.06.002","volume":"35","author":"C Proto","year":"2024","unstructured":"Proto C, Ganzinelli M, Manglaviti S, Imbimbo M, Galli G, Marabese M et al (2024) Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671). Ann Oncol 35(9):817\u2013826. https:\/\/doi.org\/10.1016\/j.annonc.2024.06.002","journal-title":"Ann Oncol"},{"issue":"9","key":"4311_CR74","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/S1470-2045(25)00300-6","volume":"26","author":"J Remon","year":"2025","unstructured":"Remon J, Bironzo P, Girard N, Bigay-Game L, Juan-Vidal O, de Castro J et al (2025) Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. Lancet Oncol 26(9):1215\u20131226. https:\/\/doi.org\/10.1016\/S1470-2045(25)00300-6","journal-title":"Lancet Oncol"},{"issue":"6","key":"4311_CR75","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","volume":"14","author":"RR Weichselbaum","year":"2017","unstructured":"Weichselbaum RR, Liang H, Deng L, Fu YX (2017) Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol 14(6):365\u2013379. https:\/\/doi.org\/10.1038\/nrclinonc.2016.211","journal-title":"Nat Rev Clin Oncol"},{"issue":"1109","key":"4311_CR76","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20200042","volume":"93","author":"S Demaria","year":"2020","unstructured":"Demaria S, Formenti SC (2020) The abscopal effect 67 years later: from a side story to center stage. Br J Radiol 93(1109):20200042. https:\/\/doi.org\/10.1259\/bjr.20200042","journal-title":"Br J Radiol"},{"issue":"1","key":"4311_CR77","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semradonc.2014.07.005","volume":"25","author":"EB Golden","year":"2015","unstructured":"Golden EB, Apetoh L (2015) Radiotherapy and immunogenic cell death. Semin Radiat Oncol 25(1):11\u201317. https:\/\/doi.org\/10.1016\/j.semradonc.2014.07.005","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"4311_CR78","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28518","volume":"3","author":"EB Golden","year":"2014","unstructured":"Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC (2014) Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 3(4):e28518. https:\/\/doi.org\/10.4161\/onci.28518","journal-title":"Oncoimmunology"},{"issue":"51","key":"4311_CR79","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1016\/j.vaccine.2015.05.105","volume":"33","author":"C Vanpouille-Box","year":"2015","unstructured":"Vanpouille-Box C, Pilones KA, Wennerberg E, Formenti SC, Demaria S (2015) In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine 33(51):7415\u20137422. https:\/\/doi.org\/10.1016\/j.vaccine.2015.05.105","journal-title":"Vaccine"},{"issue":"13","key":"4311_CR80","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, Drake CG (2015) Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16(13):e498\u2013e509. https:\/\/doi.org\/10.1016\/S1470-2045(15)00007-8","journal-title":"Lancet Oncol"},{"issue":"1","key":"4311_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ et al (2017) DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 8(1):15618. https:\/\/doi.org\/10.1038\/ncomms15618","journal-title":"Nat Commun"},{"key":"4311_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.08.011","author":"YH Bang","year":"2025","unstructured":"Bang YH, Noh JM, Lee B, Choi YL, Yang K, Pyo H et al (2025) Perioperative pembrolizumab for locally advanced thymic epithelial tumors: a single-arm, phase 2 trial. J Thorac Oncol. https:\/\/doi.org\/10.1016\/j.jtho.2025.08.011","journal-title":"J Thorac Oncol"},{"issue":"5","key":"4311_CR83","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/pon.6115","volume":"32","author":"E Arvanitou","year":"2023","unstructured":"Arvanitou E, Nikoloudi M, Tsoukalas N, Parpa E, Mystakidou K (2023) Factors associated with anxiety and depression in cancer patients: demographic factors and the role of demoralization and satisfaction with care. Psychooncology 32(5):712\u2013720. https:\/\/doi.org\/10.1002\/pon.6115","journal-title":"Psychooncology"},{"issue":"1","key":"4311_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer 5(1):95. https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"issue":"14","key":"4311_CR85","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1002\/cncr.35300","volume":"130","author":"C Sauer","year":"2024","unstructured":"Sauer C, Zsch\u00e4bitz S, Krauss J, Walle T, Haag GM, J\u00e4ger D et al (2024) Electronic health intervention to manage symptoms of immunotherapy in patients with cancer (SOFIA): results from a randomized controlled pilot trial. Cancer 130(14):2503\u20132514. https:\/\/doi.org\/10.1002\/cncr.35300","journal-title":"Cancer"},{"issue":"1","key":"4311_CR86","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/10781552211061133","volume":"29","author":"G Myers","year":"2023","unstructured":"Myers G, Stevens J, Flewelling A, Richard J, London M (2023) Evaluation and clinical impact of a pharmacist-led, interdisciplinary service focusing on education, monitoring and toxicity management of immune checkpoint inhibitors. J Oncol Pharm Pract 29(1):145\u2013154. https:\/\/doi.org\/10.1177\/10781552211061133","journal-title":"J Oncol Pharm Pract"},{"key":"4311_CR87","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-SITC2023.0781","author":"M McAdams","year":"2023","unstructured":"McAdams M, Swift S, Donahue RN, Celades C, Tsai YT, Bingham M, Szabo E, Choradia N, Zhao C, Sansone S, Feierabend C (2023) 781 A phase II, open-label trial of bintrafusp alfa (M7824) in subjects with thymoma and thymic carcinoma (trial in progress). J ImmunoTherapy Cancer. https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.0781","journal-title":"J ImmunoTherapy Cancer"},{"issue":"Suppl 16","key":"4311_CR88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e20647","volume":"41","author":"M Mcadams","year":"2023","unstructured":"Mcadams M, Swift S, Donahue RN, Celades C, Tsai YT, Bingham M et al (2023) Preliminary efficacy, safety, and immunomodulatory effects of PT-112 from a phase 2 proof of concept study in patients (pts) with thymic epithelial tumors (TETs). J Clin Oncol 41(Suppl 16):e20647","journal-title":"J Clin Oncol"},{"issue":"5","key":"4311_CR89","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1172\/JCI99538","volume":"129","author":"F Chen","year":"2019","unstructured":"Chen F, Zou Z, Du J, Su S, Shao J, Meng F et al (2019) Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Invest 129(5):2056\u20132070. https:\/\/doi.org\/10.1172\/JCI99538","journal-title":"J Clin Invest"},{"issue":"11","key":"4311_CR90","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/jcp-2023-209070","volume":"77","author":"A Weissferdt","year":"2024","unstructured":"Weissferdt A, Moran C (2024) PAX5 and CD70 are expressed in thymic carcinoma but not in atypical thymoma (WHO type B3 thymoma): an immunohistochemical analysis of 60 cases. J Clin Pathol 77(11):761\u2013765. https:\/\/doi.org\/10.1136\/jcp-2023-209070","journal-title":"J Clin Pathol"},{"issue":"3","key":"4311_CR91","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cllc.2024.12.001","volume":"26","author":"JA Marks","year":"2025","unstructured":"Marks JA, Ahn J, Reuss JE, Barbie D, Altan M, Gutierrez ME, Garassino MC, Riely GJ, Wakelee H, Liu SV, Kim C (2025) Phase II parallel arm study of sacituzumab govitecan-Hziy in patients with advanced thymoma or thymic carcinoma. Clin Lung Cancer 26(3):165\u2013167. https:\/\/doi.org\/10.1016\/j.cllc.2024.12.001","journal-title":"Clin Lung Cancer"},{"issue":"11","key":"4311_CR92","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1002\/ijc.31253","volume":"142","author":"Y Oji","year":"2018","unstructured":"Oji Y, Inoue M, Takeda Y, Hosen N, Shintani Y, Kawakami M et al (2018) WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies. Int J Cancer 142(11):2375\u20132382. https:\/\/doi.org\/10.1002\/ijc.31253","journal-title":"Int J Cancer"},{"issue":"1","key":"4311_CR93","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/cpt.3658","volume":"118","author":"J Zhu","year":"2025","unstructured":"Zhu J, Schroeder A, Frank S, Boetsch C, Jamois C, Kassir N et al (2025) Oncology dose optimization: tailored approaches to different molecular classes. Clin Pharmacol Ther 118(1):74\u201379. https:\/\/doi.org\/10.1002\/cpt.3658","journal-title":"Clin Pharmacol Ther"},{"key":"4311_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.19.00142","volume":"5","author":"A Renner","year":"2019","unstructured":"Renner A, Burotto M, Rojas C (2019) Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy? J Glob Oncol 5:1\u20135. https:\/\/doi.org\/10.1200\/JGO.19.00142","journal-title":"J Glob Oncol"},{"key":"4311_CR95","doi-asserted-by":"publisher","first-page":"S245","DOI":"10.1016\/j.annonc.2025.08.542","volume":"36","author":"S Bernatz","year":"2025","unstructured":"Bernatz S, Prudente V, Pai S, Kjaer A, Di FA, Rowan A et al (2025) Thymic health is associated with immunotherapy outcomes in patients with cancer. Ann Oncol 36:S245","journal-title":"Ann Oncol"},{"issue":"5","key":"4311_CR96","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2302892","volume":"389","author":"KA Kooshesh","year":"2023","unstructured":"Kooshesh KA, Foy BH, Sykes DB, Gustafsson K, Scadden DT (2023) Health consequences of thymus removal in adults. N Engl J Med 389(5):406\u2013417. https:\/\/doi.org\/10.1056\/NEJMoa2302892","journal-title":"N Engl J Med"},{"issue":"8","key":"4311_CR97","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/cncr.34678","volume":"129","author":"R Maniar","year":"2023","unstructured":"Maniar R, Loehrer PJ Sr. (2023) Understanding the landscape of immunotherapy in thymic epithelial tumors. Cancer 129(8):1162\u20131172. https:\/\/doi.org\/10.1002\/cncr.34678","journal-title":"Cancer"},{"key":"4311_CR98","doi-asserted-by":"publisher","first-page":"8598","DOI":"10.1200\/JCO.2023.41.16_suppl.8598","volume":"41","author":"F Ardeshir-Larijani","year":"2023","unstructured":"Ardeshir-Larijani F, Ravichandran KR, Schneider BP, Radovich M, Maniar R, Masood A et al (2023) Utilization of circulating tumor DNA (ctDNA) analysis to detect minimal residual disease post-surgery and disease progression in metastatic thymic tumors. J Clin Oncol 41:8598\u20138598. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8598","journal-title":"J Clin Oncol"},{"issue":"3","key":"4311_CR99","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1158\/0008-5472.CAN-21-1718","volume":"82","author":"JC Stadler","year":"2022","unstructured":"Stadler JC, Belloum Y, Deitert B, Sementsov M, Heidrich I, Gebhardt C et al (2022) Current and future clinical applications of ctDNA in Immuno-Oncology. Cancer Res 82(3):349\u2013358. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-1718","journal-title":"Cancer Res"},{"key":"4311_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109173","volume":"111","author":"Z Liu","year":"2022","unstructured":"Liu Z, Han Y, Dang Q, Xu H, Zhang Y, Duo M et al (2022) Roles of circulating tumor DNA in PD-1\/PD-L1 immune checkpoint Inhibitors: current evidence and future directions. Int Immunopharmacol 111:109173. https:\/\/doi.org\/10.1016\/j.intimp.2022.109173","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"4311_CR101","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41571-018-0074-3","volume":"15","author":"L Cabel","year":"2018","unstructured":"Cabel L, Proudhon C, Romano E, Girard N, Lantz O, Stern MH et al (2018) Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nat Rev Clin Oncol 15(10):639\u2013650. https:\/\/doi.org\/10.1038\/s41571-018-0074-3","journal-title":"Nat Rev Clin Oncol"},{"key":"4311_CR102","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.1200\/JCO.2021.39.15_suppl.8577","volume":"39","author":"HI Dada","year":"2021","unstructured":"Dada HI, Drusbosky L, Giaccone G (2021) Cell-free circulating tumor DNA (cfDNA) analysis of advanced thymic epithelial tumors (TETs). J Clin Oncol 39:8577","journal-title":"J Clin Oncol"},{"issue":"1","key":"4311_CR103","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005924","volume":"11","author":"L Sivapalan","year":"2023","unstructured":"Sivapalan L, Murray JC, Canzoniero JV, Landon B, Jackson J, Scott S et al (2023) Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. J Immunother Cancer 11(1):e005924. https:\/\/doi.org\/10.1136\/jitc-2022-005924","journal-title":"J Immunother Cancer"},{"issue":"23","key":"4311_CR104","doi-asserted-by":"publisher","first-page":"6909","DOI":"10.1158\/1078-0432.CCR-18-2688","volume":"25","author":"A Snyder","year":"2019","unstructured":"Snyder A, Morrissey MP, Hellmann MD (2019) Use of circulating tumor DNA for cancer immunotherapy. Clin Cancer Res 25(23):6909\u20136915. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2688","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4311_CR105","doi-asserted-by":"publisher","first-page":"19215","DOI":"10.1038\/s41598-024-69735-3","volume":"14","author":"Z Liang","year":"2024","unstructured":"Liang Z, Li J, Tang Y, Zhang Y, Chen C, Li S, Wang X, Xu X, Zhuang Z, He S, Deng B (2024) Predicting the risk category of thymoma with machine learning-based computed tomography radiomics signatures and their between-imaging phase diff erences. Sci Rep 14(1):19215. https:\/\/doi.org\/10.1038\/s41598-024-69735-3","journal-title":"Sci Rep"},{"issue":"7","key":"4311_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering12070721","volume":"12","author":"A Castello","year":"2025","unstructured":"Castello A, Manco L, Cattaneo M, Orlandi R, Rosso L, Croci GA, Florimonte L, Scribano G, Turra A, Ferrero S, Nosotti M, Carrafiello G, Castellani M, Mendogni P (2025) Machine learning models derived from [18F]FDG PET\/CT for the prediction of recurrence in patients with thymomas. Bioengineering 12(7):721. https:\/\/doi.org\/10.3390\/bioengineering12070721","journal-title":"Bioengineering"},{"key":"4311_CR107","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e20138","volume":"43","author":"F Ardeshir Larijani","year":"2025","unstructured":"Ardeshir Larijani F, Behrouzi P, Galassi L, Patel A, Muhaddesi M, Badve SS, Gokmen-Polar Y, Khorrami MH, Mesa H, Loehrer SPJ, Shin DM (2025) Leveraging AI predictive models to develop thymic tumor\u2013specific peptides mimicking COL17A1 alterations. J Clin Oncol 43:e20138-e20138. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e20138","journal-title":"J Clin Oncol"},{"issue":"14","key":"4311_CR108","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.7150\/ijbs.83468","volume":"19","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zeng B, Zhu H, Ma R, Yuan P, Chen Z, Su C, Liu Z, Yao X, Lawrence A, Liu Z, Zou J (2023) Role of glycosphingolipid biosynthesis coregulators in malignant progression of thymoma. Int J Biol Sci 19(14):4442\u20134456. https:\/\/doi.org\/10.7150\/ijbs.83468","journal-title":"Int J Biol Sci"},{"issue":"30","key":"4311_CR109","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1111\/1759-7714.15089","volume":"14","author":"DH Kim","year":"2023","unstructured":"Kim DH, Lim Y, Kim S, Ock CY, Youk J, Kim M, Kim TM, Kim DW, Kim HJ, Koh J, Jung KC, Na KJ, Kang CH, Keam B (2023) Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: a single-center, retrospective, longitudinal cohort study. Thorac Cancer 14(30):3001\u20133011. https:\/\/doi.org\/10.1111\/1759-7714.15089","journal-title":"Thorac Cancer"},{"issue":"4","key":"4311_CR110","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.cllc.2024.02.002","volume":"25","author":"Y Okuma","year":"2024","unstructured":"Okuma Y, Nomura S, Sakakibara-Konishi J, Tsukita Y, Murakami S, Hosomi Y et al (2024) Artemis: a multicenter, open-label, single-arm, phase II study to evaluate the efficacy and safety of first-line carboplatin\/paclitaxel\/lenvatinib\/pembrolizumab combination for previously untreated advanced or recurrent thymic carcinomas. Clin Lung Cancer 25(4):389\u2013394. https:\/\/doi.org\/10.1016\/j.cllc.2024.02.002","journal-title":"Clin Lung Cancer"},{"key":"4311_CR111","doi-asserted-by":"publisher","first-page":"TPS130","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8130","volume":"43","author":"M Duruisseaux","year":"2025","unstructured":"Duruisseaux M, Besse B, Girard N, Dansin E, Cousin S, Mazieres J et al (2025) IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers\u2014The B3 Thymomas and Thymic Carcinomas Cohort. J Clin Oncol 43:TPS130\u2013TPS130. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.TPS8130","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s00262-026-04407-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000}}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04311-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04311-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04311-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:28:25Z","timestamp":1778066905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04311-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":111,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4311"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04311-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00262-026-04407-x","URL":"https:\/\/doi.org\/10.1007\/s00262-026-04407-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"110"}}